Q3 Earnings Estimate for Surmodics Issued By Zacks Research

Surmodics, Inc. (NASDAQ:SRDX - Free Report) - Research analysts at Zacks Research issued their Q3 2025 EPS estimates for shares of Surmodics in a research note issued to investors on Wednesday, May 21st. Zacks Research analyst D. Dey anticipates that the company will post earnings per share of ($0.18) for the quarter. The consensus estimate for Surmodics' current full-year earnings is $0.20 per share. Zacks Research also issued estimates for Surmodics' Q4 2025 earnings at ($0.09) EPS, FY2025 earnings at ($0.44) EPS, Q1 2026 earnings at ($0.11) EPS, Q3 2026 earnings at $0.02 EPS, Q4 2026 earnings at $0.06 EPS, FY2026 earnings at ($0.01) EPS, Q1 2027 earnings at $0.02 EPS and Q2 2027 earnings at $0.12 EPS.

Several other research firms have also recently issued reports on SRDX. Needham & Company LLC restated a "hold" rating on shares of Surmodics in a research note on Wednesday, April 30th. Lake Street Capital upgraded shares of Surmodics from a "hold" rating to a "buy" rating and set a $43.00 target price on the stock in a research note on Friday, March 7th. Finally, Wall Street Zen initiated coverage on shares of Surmodics in a research note on Monday, February 3rd. They set a "hold" rating on the stock. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $43.00.

Surmodics Stock Up 1.2%

SRDX stock traded up $0.34 during midday trading on Monday, hitting $29.54. The company's stock had a trading volume of 23,106 shares, compared to its average volume of 277,826. The company has a market cap of $422.44 million, a PE ratio of -29.10 and a beta of 1.32. Surmodics has a 12 month low of $26.00 and a 12 month high of $42.44. The company has a current ratio of 5.45, a quick ratio of 4.29 and a debt-to-equity ratio of 0.26. The firm's 50-day moving average is $28.76 and its 200-day moving average is $33.69.

Surmodics (NASDAQ:SRDX - Get Free Report) last announced its quarterly earnings data on Wednesday, April 30th. The company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.07). The firm had revenue of $28.09 million during the quarter, compared to analysts' expectations of $32.23 million. Surmodics had a negative return on equity of 4.39% and a negative net margin of 11.48%.

Hedge Funds Weigh In On Surmodics

Several hedge funds and other institutional investors have recently bought and sold shares of SRDX. Hudson Bay Capital Management LP bought a new position in Surmodics during the 4th quarter valued at about $11,880,000. Bardin Hill Management Partners LP bought a new position in shares of Surmodics in the 4th quarter worth approximately $7,440,000. Eisler Capital Management Ltd. bought a new position in shares of Surmodics in the 4th quarter worth approximately $5,394,000. Balyasny Asset Management L.P. bought a new position in shares of Surmodics in the 4th quarter worth approximately $4,921,000. Finally, Groupe la Francaise bought a new position in shares of Surmodics in the 1st quarter worth approximately $3,648,000. Institutional investors own 96.63% of the company's stock.

Surmodics Company Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).